Compare Stocks: VRAX, FEMY, MBAI, and HSCS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$2.95 -2.0%	$4.27	$2.64 ▼ $22.20	$8.91M	-2.08	48,563 shs	20,557 shs
HSCS HeartSciences	$2.00 -12.3%	$2.32	$1.63 ▼ $3.93	$7.80M	1.79	972,342 shs	44,733 shs
MBAI Check-Cap	$1.41 +8.5%	$1.25	$0.60 ▼ $3.92	$10.90M	0.68	1.10 million shs	83,268 shs
VRAX Virax Biolabs Group	$2.77 -4.8%	$3.92	$2.50 ▼ $21.75	$2.22M	1.35	1.15 million shs	76,804 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	-1.31%	+8.27%	-26.23%	-66.49%	-84.46%
HSCS HeartSciences	+9.62%	+5.56%	-15.56%	+17.53%	-36.84%
MBAI Check-Cap	+13.04%	+25.00%	+12.07%	-12.75%	+129,999,900.00%
VRAX Virax Biolabs Group	-2.35%	-0.68%	-6.43%	-13.78%	-85.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$2.95 -2.0%	$4.27	$2.64 ▼ $22.20	$8.91M	-2.08	48,563 shs	20,557 shs
HSCS HeartSciences	$2.00 -12.3%	$2.32	$1.63 ▼ $3.93	$7.80M	1.79	972,342 shs	44,733 shs
MBAI Check-Cap	$1.41 +8.5%	$1.25	$0.60 ▼ $3.92	$10.90M	0.68	1.10 million shs	83,268 shs
VRAX Virax Biolabs Group	$2.77 -4.8%	$3.92	$2.50 ▼ $21.75	$2.22M	1.35	1.15 million shs	76,804 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	-1.31%	+8.27%	-26.23%	-66.49%	-84.46%
HSCS HeartSciences	+9.62%	+5.56%	-15.56%	+17.53%	-36.84%
MBAI Check-Cap	+13.04%	+25.00%	+12.07%	-12.75%	+129,999,900.00%
VRAX Virax Biolabs Group	-2.35%	-0.68%	-6.43%	-13.78%	-85.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FEMY Femasys	2.50	Moderate Buy	$106.67	3,515.82% Upside
HSCS HeartSciences	2.00	Hold	$8.00	300.00% Upside
MBAI Check-Cap	1.00	Sell	N/A	N/A
VRAX Virax Biolabs Group	2.00	Hold	$25.00	802.53% Upside

Current Analyst Ratings Breakdown

Latest VRAX, FEMY, MBAI, and HSCS Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/31/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	MBAI Check-Cap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/6/2026	VRAX Virax Biolabs Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	HSCS HeartSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/3/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/18/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FEMY Femasys	$2.29M	3.89	N/A	N/A	$2.01 per share	1.47
HSCS HeartSciences	N/A	N/A	N/A	N/A	$0.07 per share	N/A
MBAI Check-Cap	N/A	N/A	$0.70 per share	2.02	$0.47 per share	N/A
VRAX Virax Biolabs Group	$10K	221.60	N/A	N/A	$42.23 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FEMY Femasys	-$18.63M	-$5.40	N/A	N/A	N/A	-521.97%	-258.08%	-73.72%	8/12/2026 (Estimated)
HSCS HeartSciences	-$9.14M	-$3.94	N/A	N/A	N/A	N/A	-358.60%	-144.82%	9/10/2026 (Estimated)
MBAI Check-Cap	$4.14M	-$2.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	-$5.02M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VRAX, FEMY, MBAI, and HSCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	FEMY Femasys	-$1.2667	N/A	N/A	N/A	$0.73 million	N/A
7/23/2026	Q4 2026	HSCS HeartSciences	-$0.66	-$0.88	-$0.22	-$0.87	$0.05 million	N/A
7/3/2026	Q4 2026	VRAX Virax Biolabs Group	-$1.75	-$0.1950	+$1.5550	-$0.1950	$0.00 million	$0.01 million
5/8/2026	Q1 2026	FEMY Femasys	-$1.3334	$0.0980	+$1.4314	N/A	$0.77 million	$0.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FEMY Femasys	N/A	N/A	N/A	N/A	N/A
HSCS HeartSciences	N/A	N/A	N/A	N/A	N/A
MBAI Check-Cap	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FEMY Femasys	0.53	3.91	1.98
HSCS HeartSciences	N/A	0.53	0.40
MBAI Check-Cap	N/A	0.05	0.05
VRAX Virax Biolabs Group	N/A	9.97	9.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FEMY Femasys	65.27%
HSCS HeartSciences	17.24%
MBAI Check-Cap	1.07%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
FEMY Femasys	7.75%
HSCS HeartSciences	4.90%
MBAI Check-Cap	0.48%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FEMY Femasys	30	3.02 million	2.79 million	Not Optionable
HSCS HeartSciences	10	3.90 million	3.71 million	Not Optionable
MBAI Check-Cap	80	7.73 million	7.69 million	N/A
VRAX Virax Biolabs Group	5	800,000	438,000	Not Optionable

VRAX, FEMY, MBAI, and HSCS Headlines

Recent News About These Companies

Virax Biolabs Calls August 14 EGM to Approve Major Share Capital Increase

August 2, 2026 | theglobeandmail.com

Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Declines By 58.7%

July 27, 2026 | americanbankingnews.com

RedChip Companies, Inc.: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV

July 20, 2026 | finanznachrichten.de

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

July 17, 2026 | tipranks.com

Virax BioLabs Group Limited: Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

July 16, 2026 | finanznachrichten.de

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

July 16, 2026 | prnewswire.com

Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants

July 10, 2026 | tipranks.com

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

July 10, 2026 | prnewswire.com

Virax Biolabs Group Limited Ordinary Shares (VRAX) Institutional Holdings

July 10, 2026 | nasdaq.com

Virax Biolabs stock skyrockets 100% on exclusive distribution agreement

July 9, 2026 | msn.com

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

July 9, 2026 | prnewswire.com

Virax Biolabs shares double after exclusive Fosun distribution agreement (VRAX)

July 9, 2026 | msn.com

Why this biotech stock more than tripled on Thursday

July 9, 2026 | invezz.comI

Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement

July 9, 2026 | quiverquant.comQ

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

July 9, 2026 | prnewswire.com

Virax Biolabs Group announces 1-for-25 share consolidation

June 25, 2026 | msn.com

Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing

June 24, 2026 | tipranks.com

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

June 24, 2026 | prnewswire.com

Virax BioLabs Group Limited: Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes

May 26, 2026 | finanznachrichten.de

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

May 26, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, FEMY, MBAI, and HSCS Company Descriptions

Femasys NASDAQ:FEMY

$2.95 -0.06 (-1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$2.96 +0.00 (+0.17%)

As of 04:23 PM Eastern

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

HeartSciences NASDAQ:HSCS

$2.00 -0.28 (-12.28%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 +0.00 (+0.25%)

As of 04:13 PM Eastern

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Check-Cap NASDAQ:MBAI

$1.41 +0.11 (+8.46%)

Closing price 03:59 PM Eastern

Extended Trading

$1.32 -0.09 (-6.03%)

As of 04:57 PM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Virax Biolabs Group NASDAQ:VRAX

$2.77 -0.14 (-4.81%)

Closing price 04:00 PM Eastern

Extended Trading

$2.87 +0.10 (+3.54%)

As of 04:56 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRAX, FEMY, MBAI, and HSCS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRAX, FEMY, MBAI, and HSCS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRAX, FEMY, MBAI, and HSCS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, FEMY, MBAI, and HSCS Company Descriptions

Femasys NASDAQ:FEMY

HeartSciences NASDAQ:HSCS

Check-Cap NASDAQ:MBAI

Virax Biolabs Group NASDAQ:VRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRAX, FEMY, MBAI, and HSCS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRAX, FEMY, MBAI, and HSCS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRAX, FEMY, MBAI, and HSCS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, FEMY, MBAI, and HSCS Company Descriptions

Femasys NASDAQ:FEMY

HeartSciences NASDAQ:HSCS

Check-Cap NASDAQ:MBAI

Virax Biolabs Group NASDAQ:VRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools